<DOC>
	<DOCNO>NCT00148993</DOCNO>
	<brief_summary>The goal study apply allogeneic tumor cell vaccination immunotherapy patient micro-metastatic disease and/or patient high risk disease progression . The present study use allogeneic tumor cell line tumor cell vaccine share MHC determinants patient aim overcome possible restriction antigen presentation .</brief_summary>
	<brief_title>Allogeneic Tumor Cell Vaccination Patients With Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>Patients measurable metastatic disease disease resistant chemotherapy minimal residual disease high risk relapse . Karnofsky le 60 % . Unrelated condition require use cytotoxic agent immunosuppressive agent may interfere optimal immune response .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2005</verification_date>
	<keyword>Tumor cell vaccine</keyword>
</DOC>